Cargando…
Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis
BACKGROUND AND OBJECTIVE: Difelikefalin, a selective kappa-opioid receptor agonist, is the first approved treatment for moderate-to-severe pruritus in patients with end-stage renal disease (ESRD) on hemodialysis (HD) in the USA and Europe. The purpose of this open-label study was to investigate the...
Autores principales: | Stark, Jeffrey G., Noonan, Patrick K., Spencer, Robert H., Bhaduri, Sarbani, O’Connor, Stephen J., Menzaghi, Frédérique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450003/ https://www.ncbi.nlm.nih.gov/pubmed/37369955 http://dx.doi.org/10.1007/s40262-023-01262-2 |
Ejemplares similares
-
Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients
por: Fishbane, Steven, et al.
Publicado: (2020) -
Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study
por: Weiner, Daniel E., et al.
Publicado: (2022) -
Assessment of the physical dependence potential of difelikefalin: Randomized placebo‐controlled study in patients receiving hemodialysis
por: Spencer, Robert H., et al.
Publicado: (2023) -
Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies
por: Topf, Joel, et al.
Publicado: (2022) -
Metabolism, Excretion, and Pharmacokinetics of [(14)C]‐Cefiderocol (S‐649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration
por: Miyazaki, Shiro, et al.
Publicado: (2019)